CoChat

NMDA Receptor Internalization by Autoantibodies: A Reversible Mechanism Underlying Psychosis?

Open access
Masdeu, Joseph C., Dalmau, Josep, Berman, Karen F. · 2016 · Trends in Neurosciences
Cited by 91

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

Abstract

Since the early 1990s it has been postulated that hypofunction of N-methyl-D-aspartate (NMDA) receptors in brain networks supporting perception and cognition underlies schizophrenic psychosis. Recently, NMDA receptor hypofunction was described in patients with psychotic manifestations who exhibited autoantibodies binding the GluN1 subunit of the receptor, and who improved when the level of these antibodies was lowered by immunomodulation. In this disorder, NMDA receptor antibodies decrease the availability of NMDA receptors by internalizing them. Here we review this mechanism as well as data supporting or refuting the possibility that this disorder, or similar autoimmune disorders affecting synaptic proteins which are therefore treatable with immunomodulation, could account for some cases of idiopathic psychosis. We also suggest methodological approaches to clarify this issue.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.tins.2016.02.006

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 41 references

Research works printed but not linked: 70

  1. Hansen, 2014, Distinct functional and pharmacological properties of Triheteromeric GluN1/GluN2A/GluN2B NMDA receptors, Neuron, 81, 1084, 10.1016/j.neuron.2014.01.035 · DOI · Paper page
  2. Karakas, 2014, Crystal structure of a heterotetrameric NMDA receptor ion channel, Science, 344, 992, 10.1126/science.1251915 · DOI · Paper page
  3. Lee, 2014, NMDA receptor structures reveal subunit arrangement and pore architecture, Nature, 511, 191, 10.1038/nature13548 · DOI · Paper page
  4. Pachernegg, 2012, GluN3 subunit-containing NMDA receptors: not just one-trick ponies, Trends Neurosci., 35, 240, 10.1016/j.tins.2011.11.010 · DOI
  5. Wang, 2015, Contribution of NMDA receptors to dorsolateral prefrontal cortical networks in primates, Neurosci. Bull., 31, 191, 10.1007/s12264-014-1504-6 · DOI · Paper page
  6. Viaccoz, 2014, Clinical specificities of adult male patients with NMDA receptor antibodies encephalitis, Neurology, 82, 556, 10.1212/WNL.0000000000000126 · DOI · Paper page
  7. Pathmanandavel, 2015, Antibodies to surface dopamine-2 receptor and N-methyl-d-aspartate receptor in the first episode of acute psychosis in children, Biol. Psychiatry, 77, 537, 10.1016/j.biopsych.2014.07.014 · DOI
  8. Kayser, 2013, Frequency and characteristics of isolated psychiatric episodes in anti- N-methyl-d-aspartate receptor encephalitis, JAMA Neurol., 70, 1133, 10.1001/jamaneurol.2013.3216 · DOI · Paper page
  9. Zandi, 2011, Disease-relevant autoantibodies in first episode schizophrenia, J. Neurol., 258, 686, 10.1007/s00415-010-5788-9 · DOI · Paper page
  10. Jablensky, 2000, Psychotic disorders in urban areas: an overview of the Study on Low Prevalence Disorders, Aust. N. Z. J. Psychiatry, 34, 221, 10.1080/j.1440-1614.2000.00728.x · doi:10.1080/j.1440-1614.2000.00728.x · Paper page
  11. de Witte, 2015, Absence of N-methyl-d-aspartate receptor IgG autoantibodies in schizophrenia: the importance of cross-validation studies, JAMA Psychiatry, 72, 731, 10.1001/jamapsychiatry.2015.0526 · doi:10.1001/jamapsychiatry.2015.0526
  12. Masdeu, 2012, Serum IgG antibodies against the NR1 subunit of the NMDA receptor not detected in schizophrenia, Am. J. Psychiatry, 169, 1120, 10.1176/appi.ajp.2012.12050646 · DOI · Paper page
  13. Rhoads, 2011, Lack of anti-NMDA receptor autoantibodies in the serum of subjects with schizophrenia, Schizophr. Res., 129, 213, 10.1016/j.schres.2010.12.018 · DOI
  14. Steiner, 2013, Increased prevalence of diverse N-methyl-d-aspartate glutamate receptor antibodies in patients with an initial diagnosis of schizophrenia: specific relevance of IgG NR1a antibodies for distinction from N-methyl-d-aspartate glutamate receptor encephalitis, JAMA Psychiatry, 70, 271, 10.1001/2013.jamapsychiatry.86 · DOI · Paper page
  15. Dahm, 2014, Seroprevalence of autoantibodies against brain antigens in health and disease, Ann. Neurol., 76, 82, 10.1002/ana.24189 · DOI · Paper page
  16. Eisenberg, 2010, Catechol-O-methyltransferase valine158methionine genotype and resting regional cerebral blood flow in medication-free patients with schizophrenia, Biol. Psychiatry, 67, 287, 10.1016/j.biopsych.2009.08.039 · DOI
  17. Martucci, 2006, N-Methyl-d-aspartate receptor NR2B subunit gene GRIN2B in schizophrenia and bipolar disorder: polymorphisms and mRNA levels, Schizophr. Res., 84, 214, 10.1016/j.schres.2006.02.001 · DOI
  18. Javitt, 2015, Neurophysiological models for new treatment development in schizophrenia: early sensory approaches, Ann. N. Y. Acad. Sci., 1344, 92, 10.1111/nyas.12689 · DOI
  19. Naatanen, 2009, Central auditory dysfunction in schizophrenia as revealed by the mismatch negativity (MMN) and its magnetic equivalent MMNm: a review, Int. J. Neuropsychopharmacol., 12, 125, 10.1017/S1461145708009322 · DOI · Paper page
  20. Lisman, 2010, A thalamo-hippocampal-ventral tegmental area loop may produce the positive feedback that underlies the psychotic break in schizophrenia, Biol. Psychiatry, 68, 17, 10.1016/j.biopsych.2010.04.007 · DOI · Paper page
  21. Weickert, 2013, Molecular evidence of N-methyl-d-aspartate receptor hypofunction in schizophrenia, Mol. Psychiatry, 18, 1185, 10.1038/mp.2012.137 · DOI · Paper page
  22. Law, 2001, Asymmetrical reductions of hippocampal NMDAR1 glutamate receptor mRNA in the psychoses, Neuroreport, 12, 2971, 10.1097/00001756-200109170-00043 · DOI · Paper page
  23. Papaleo, 2012, Mouse models of genetic effects on cognition: relevance to schizophrenia, Neuropharmacology, 62, 1204, 10.1016/j.neuropharm.2011.04.025 · DOI
  24. Rotaru, 2012, The role of glutamatergic inputs onto parvalbumin-positive interneurons: relevance for schizophrenia, Rev. Neurosci., 23, 97, 10.1515/revneuro-2011-0059 · DOI · Paper page
  25. Tandon, 2009, Schizophrenia, “just the facts” 4. Clinical features and conceptualization, Schizophr. Res., 110, 1, 10.1016/j.schres.2009.03.005 · DOI · Paper page
  26. Buckley, 2001, Potassium channel antibodies in two patients with reversible limbic encephalitis, Ann. Neurol., 50, 73, 10.1002/ana.1097 · DOI · Paper page
  27. Lai, 2009, AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location, Ann. Neurol., 65, 424, 10.1002/ana.21589 · DOI · Paper page
  28. Petit-Pedrol, 2014, Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterization of the antigen, and analysis of the effects of antibodies, Lancet Neurol., 13, 276, 10.1016/S1474-4422(13)70299-0 · DOI · Paper page
  29. Bien, 2012, Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis, Brain, 135, 1622, 10.1093/brain/aws082 · DOI · Paper page
  30. Camdessanche, 2011, Brain immunohistopathological study in a patient with anti-NMDAR encephalitis, Eur. J. Neurol., 18, 929, 10.1111/j.1468-1331.2010.03180.x · DOI
  31. Martinez-Hernandez, 2011, Analysis of complement and plasma cells in the brain of patients with anti-NMDAR encephalitis, Neurology, 77, 589, 10.1212/WNL.0b013e318228c136 · DOI · Paper page
  32. Lim, 2015, Autoimmune encephalopathies, Pediatr. Clin. North Am., 62, 667, 10.1016/j.pcl.2015.03.011 · DOI
  33. Gleichman, 2012, Anti-NMDA receptor encephalitis antibody binding is dependent on amino acid identity of a small region within the GluN1 amino terminal domain, J. Neurosci., 32, 11082, 10.1523/JNEUROSCI.0064-12.2012 · DOI · Paper page
  34. Gresa-Arribas, 2014, Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study, Lancet Neurol., 13, 167, 10.1016/S1474-4422(13)70282-5 · DOI · Paper page
  35. Moscato, 2014, Acute mechanisms underlying antibody effects in anti-N-methyl-d-aspartate receptor encephalitis, Ann. Neurol., 76, 108, 10.1002/ana.24195 · DOI · Paper page
  36. Planaguma, 2015, Human N-methyl-d-aspartate receptor antibodies alter memory and behaviour in mice, Brain, 138, 94, 10.1093/brain/awu310 · DOI · Paper page
  37. Rose, 1993, Defining criteria for autoimmune diseases (Witebsky's postulates revisited), Immunol. Today, 14, 426, 10.1016/0167-5699(93)90244-F · DOI · Paper page
  38. Pruss, 2010, Retrospective analysis of NMDA receptor antibodies in encephalitis of unknown origin, Neurology, 75, 1735, 10.1212/WNL.0b013e3181fc2a06 · DOI · Paper page
  39. Dalmau, 2011, Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis, Lancet Neurol., 10, 63, 10.1016/S1474-4422(10)70253-2 · DOI · Paper page
  40. Hafner, 2013, ABC Schizophrenia study: an overview of results since 1996, Soc. Psychiatry Psychiatr. Epidemiol., 48, 1021, 10.1007/s00127-013-0700-4 · DOI
  41. Novotna, 2015, Poor early relapse recovery affects onset of progressive disease course in multiple sclerosis, Neurology, 85, 722, 10.1212/WNL.0000000000001856 · DOI
  42. Lebon, 2012, Anti-N-methyl-d-aspartate (NMDA) receptor encephalitis mimicking a primary psychiatric disorder in an adolescent, J. Child Neurol., 27, 1607, 10.1177/0883073812438099 · DOI
  43. Tidswell, 2013, Early recognition of anti-N-methyl-d-aspartate (NMDA) receptor encephalitis presenting as acute psychosis, Australas Psychiatry, 21, 596, 10.1177/1039856213506502 · DOI
  44. Barry, 2011, Anti-NMDA receptor encephalitis: an important differential diagnosis in psychosis, Br. J. Psychiatry, 199, 508, 10.1192/bjp.bp.111.092197 · DOI
  45. Knight, 2007, Rationale for a trial of immunosuppressive therapy in acute schizophrenia, Mol. Psychiatry, 12, 424, 10.1038/sj.mp.4001959 · DOI
  46. Saetre, 2007, Inflammation-related genes up-regulated in schizophrenia brains, BMC Psychiatry, 7, 46, 10.1186/1471-244X-7-46 · DOI · Paper page
  47. Bloomfield, 2016, Microglial activity in people at ultra high risk of psychosis and in schizophrenia: an [11C]PBR28 PET brain imaging study, Am. J. Psychiatry, 173, 44, 10.1176/appi.ajp.2015.14101358 · DOI · Paper page
  48. Pollak, 2014, Prevalence of anti-N-methyl-d-aspartate (NMDA) receptor [corrected] antibodies in patients with schizophrenia and related psychoses: a systematic review and meta-analysis, Psychol. Med., 44, 2475, 10.1017/S003329171300295X · DOI · Paper page
  49. Tsutsui, 2012, Anti-NMDA-receptor antibody detected in encephalitis, schizophrenia, and narcolepsy with psychotic features, BMC Psychiatry, 12, 37, 10.1186/1471-244X-12-37 · DOI · Paper page
  50. Ransohoff, 2012, The anatomical and cellular basis of immune surveillance in the central nervous system, Nat. Rev. Immunol., 12, 623, 10.1038/nri3265 · DOI · Paper page
  51. Leypoldt, 2015, Autoimmune encephalopathies, Ann. N. Y. Acad. Sci., 1338, 94, 10.1111/nyas.12553 · DOI · Paper page
  52. Zandi, 2015, N-Methyl-d-aspartate receptor autoantibodies in psychiatric illness, Biol. Psychiatry
  53. Joubert, 2015, Clinical spectrum of encephalitis associated with antibodies against the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor: case series and review of the literature, JAMA Neurol., 72, 1163, 10.1001/jamaneurol.2015.1715 · DOI
  54. Bataller, 2010, Reversible paraneoplastic limbic encephalitis associated with antibodies to the AMPA receptor, Neurology, 74, 265, 10.1212/WNL.0b013e3181cb3e52 · DOI
  55. Lancaster, 2011, Antibodies to metabotropic glutamate receptor 5 in the Ophelia syndrome, Neurology, 77, 1698, 10.1212/WNL.0b013e3182364a44 · DOI · Paper page
  56. Jarius, 2015, Psychotic syndrome associated with anti-Ca/ARHGAP26 and voltage-gated potassium channel antibodies, J. Neuroimmunol., 286, 79, 10.1016/j.jneuroim.2015.07.009 · doi:10.1016/j.jneuroim.2015.07.009
  57. Hedegaard, 2012, Molecular pharmacology of human NMDA receptors, Neurochem. Int., 61, 601, 10.1016/j.neuint.2011.11.016 · DOI
  58. Zandi, 2015, Clinical relevance of serum antibodies to extracellular N-methyl-d-aspartate receptor epitopes, J. Neurol. Neurosurg. Psychiatry, 86, 708, 10.1136/jnnp-2014-308736 · DOI
  59. Najjar, 2013, Neuropsychiatric autoimmune encephalitis without VGKC-complex, NMDAR, and GAD autoantibodies: case report and literature review, Cogn. Behav. Neurol., 26, 36, 10.1097/WNN.0b013e31828b6531 · DOI
  60. Ellaithy, 2015, Positive allosteric modulators of metabotropic glutamate 2 receptors in schizophrenia treatment, Trends Neurosci., 38, 506, 10.1016/j.tins.2015.06.002 · DOI
  61. Banerjee, 2015, Src kinase as a mediator of convergent molecular abnormalities leading to NMDAR hypoactivity in schizophrenia, Mol. Psychiatry, 20, 1091, 10.1038/mp.2014.115 · DOI · Paper page
  62. Pitcher, 2011, Schizophrenia susceptibility pathway neuregulin 1–ErbB4 suppresses Src upregulation of NMDA receptors, Nat. Med., 17, 470, 10.1038/nm.2315 · DOI · Paper page
  63. Hahn, 2006, Altered neuregulin 1–erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia, Nat. Med., 12, 824, 10.1038/nm1418 · DOI · Paper page
  64. Labrie, 2010, The involvement of the NMDA receptor d-serine/glycine site in the pathophysiology and treatment of schizophrenia, Neurosci. Biobehav. Rev., 34, 351, 10.1016/j.neubiorev.2009.08.002 · DOI
  65. Watabe-Uchida, 2012, Whole-brain mapping of direct inputs to midbrain dopamine neurons, Neuron, 74, 858, 10.1016/j.neuron.2012.03.017 · DOI · Paper page
  66. Kodangattil, 2013, Spike timing-dependent plasticity at GABAergic synapses in the ventral tegmental area, J. Physiol., 591, 4699, 10.1113/jphysiol.2013.257873 · DOI
  67. Olson, 2007, Topographical organization of GABAergic neurons within the ventral tegmental area of the rat, Synapse, 61, 87, 10.1002/syn.20345 · DOI · Paper page
  68. Tatard-Leitman, 2015, Pyramidal cell selective ablation of N-methyl-d-aspartate receptor 1 causes increase in cellular and network excitability, Biol. Psychiatry, 77, 556, 10.1016/j.biopsych.2014.06.026 · DOI · Paper page
  69. Hafner, 1995, Epidemiology of early-onset schizophrenia, Eur. Arch. Psychiatry Clin. Neurosci., 245, 80, 10.1007/BF02190734 · DOI · Paper page
  70. Graus, 2001, Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients, Brain, 124, 1138, 10.1093/brain/124.6.1138 · DOI · Paper page

Cited by

Metadata

Authors
Masdeu, J. C., Dalmau, J., & Berman, K. F.
Venue
Trends in Neurosciences
Publisher
Elsevier BV
Published
2016-05
Volume
39
Issue
5
Pages
300-310
ISSN
0166-2236 (ISSN-L)
OpenAlex
W2343055661
Cited by
91
References
41
FWCI
2.91
Type
journal article
Language
en
Open access
green
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.